Veradermics Quarterly Cash Flow Statement
NYSE: MANEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
130.90+4.27 (+3.37%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Veradermics free cash flow
In the quarter ended Jun 30, 2026, Veradermics generated -$14.5 million of operating cash flow and spent $21,000 on capital expenditures. That left free cash flow of -$14.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
Veradermics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q2 20252025-06-30 | Q1 20252025-03-31 |
|---|---|---|---|---|
| Net Income | -23.50M | -27.23M | -15.64M | -12.40M |
| Net Income growth (YoY) | — | — | — | — |
| Stock-Based Compensation | 3.52M | 5.26M | 115.00K | 213.00K |
| Change in Working Capital | 6.38M | 3.30M | -1.93M | -614.00K |
| Operating Cash Flow | -14.49M | -21.17M | -15.64M | -13.32M |
| Capital Expenditures | -21.00K | 0 | 0 | -19.00K |
| Investing Cash Flow | -277.29M | -101.30M | -8.33M | -15.75M |
| Financing Cash Flow | 442.70M | 269.11M | 129.00K | 8.42M |
| Net Change in Cash | 150.92M | 146.65M | -23.84M | -20.64M |
| Free Cash Flow | -14.51M | -21.17M | -15.64M | -13.34M |
This table shows 4 quarterly periods of Veradermics's cash flow statement, from Q2 2026 back to Q1 2025, across 9 line items including net income, stock-based compensation, change in working capital. Values in USD; B = billions, M = millions. Fiscal periods follow MANE's reporting calendar. What is a cash flow statement?